HOME ABOUT CONTACT PREVIOUS ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Molecular Marvel       » Biogas beats Bioethanol       » Brain 'switch' can Turn off Drug Addiction (Eye on China)       » Novel Imaging Technology REFI takes Clinicians closer to detecting Stage 0 Tumour Lesions (Eye on China)      
EYE ON CHINA
WILEX Inc. and GeneDiagnostics Inc. enter into partnership for the IVD approval and distribution of serum HER-2/neu test
WILEX AG announced that its US subsidiary WILEX Inc., Cambridge, MA, has entered into an exclusive distribution agreement with GeneDiagnostics Inc. for the commercialization of the serum HER-2/neu ELISA test in China. This biomarker test is FDA cleared in the USA, carries the CE mark for the European market, and is currently for Research Use Only in the Chinese market. GeneDiagnostics plans to conduct clinical studies in leading hospitals in China for the IVD clearance through the State Food and Drug Administration in China (SFDA) as part of the terms. GeneDiagnostics is a clinical research and service provider based in Hangzhou, China, and has well-established business relationships with major hospitals.

The serum HER-2/neu test measures the serum HER-2/neu level for the management and monitoring of patients with metastatic breast cancer (MBC). HER-2 (Human Epidermal Growth Factor Receptor 2) is a protein found on some types of cancer cells, especially breast cancer cells. MBC patients who overexpress the HER-2/neu protein tend to have a worse prognosis and a more aggressive disease. The test measures changes in the HER-2 status with increasing serum levels of HER-2/neu being reflective of cancer progression while decreasing serum levels being reflective of therapy response. As the HER-2 tumour status may change between primary and metastatic breast cancer tumours, the serum HER-2/neu ELISA test can help monitor these changes in HER-2/neu levels and aid doctors in managing new treatment options. This test offers laboratories an efficient, reliable and cost-transparent possibility for the measurement of HER-2/neu in serum with no need of further equipment.

Professor Olaf G. Wilhelm, CEO of WILEX Inc. and WILEX AG, comments: “The Chinese market is expected to be one of the fastest growing pharma markets in the world. Therefore, we are pleased to have in GeneDiagnostics a competent partner to pursue an IVD approval for our serum HER-2/neu test as well as to distribute the test in this key market.”

“According to the latest statistics from the Chinese Ministry of Health 126,000 new cases of breast cancer were reported each year. This corresponds to roughly one-tenth of the world’s total and is expected to increase by at least 4% annually. We look forward to introducing this HER-2/neu ELISA test into the Chinese market as we believe that it can help physicians administer targeted treatments to carefully diagnosed patients with metastatic breast cancer”, said Dr Mark Han, President and Chief Scientist of GeneDiagnostics Inc.

Click here for the complete issue.

EDITORS' CHOICE  

Credits to: American Chemical Society
COLUMNS  

APBN Editorial Calendar 2015
Trends and Predictions for 2015 Robotics in Healthcare Nutrition Universal Health Coverage
Start-Up Biotech Companies Preventative and Translational Medicine Biofuels ASEAN Economic Community and Asia's Life Sciences Industry
Big Data: Healthcare and Drug Development Antibody Engineering in Japan Christmas Edition
APBN Editorial Calendar 2016
Korea's Biotechnology Industry Nutrition and Allergies: Are we, Too Clean? Medical Devices and Technology: Innovation that leaves an Inspiration Tobacco Smoking: The 'Real' Cost of One Cigarette
Life-Saving Opportunities: A Guide to Regenerative Medicine Occupational Health Water Technology Olympics: Evolution of Sports
Respiratory: Seasonal flu viruses
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy